Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
February 23, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
2020 revenue of $353.9 million, compared to $306.5 million in 2019Fourth quarter revenue of $85.7 million, compared to $87.9 million in 20192020 GAAP net income of $106.0 million, compared to $94.2...
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 08, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to...
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
February 01, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial...
Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors
November 23, 2020 17:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214
November 18, 2020 17:40 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 03, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication
September 10, 2020 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 28, 2020 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...